{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:10:20Z","timestamp":1792807820575,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12072-021-10223-5","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T11:02:56Z","timestamp":1627038176000},"page":"833-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"10223_CR1","volume-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report, 2017. Geneva: Switzerland World Health Organization; 2017"},{"key":"10223_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","volume":"67","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection\u2014Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67:773\u2013777","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10223_CR3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/liv.13253","volume":"36","author":"TH Su","year":"2016","unstructured":"Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755\u20131764","journal-title":"Liver Int"},{"key":"10223_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1517\/14656566.2016.1118056","volume":"17","author":"YC Chen","year":"2016","unstructured":"Chen YC, Liaw YF. Pharmacotherapeutic options for hepatitis B. Expert Opin Pharmacother. 2016;17:355\u2013367","journal-title":"Expert Opin Pharmacother"},{"key":"10223_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","volume":"70","author":"TC Yip","year":"2019","unstructured":"Yip TC, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361\u2013370","journal-title":"J Hepatol"},{"key":"10223_CR6","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u20131332","journal-title":"Gut"},{"key":"10223_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425\u2013434","journal-title":"Hepatology"},{"issue":"2","key":"10223_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol.\u00a02017;67(2):370\u2013398","journal-title":"J Hepatol"},{"key":"10223_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u2013283","journal-title":"Hepatology"},{"key":"10223_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10223_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398","journal-title":"Hepatol Int"},{"key":"10223_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u2013561. https:\/\/doi.org\/10.1007\/s12072-012-9365-4","journal-title":"Hepatol Int"},{"key":"10223_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.510300221","volume":"30","author":"YF Liaw","year":"1999","unstructured":"Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567\u2013572","journal-title":"Hepatology"},{"key":"10223_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/1471-2407-11-398","volume":"11","author":"CT Yeh","year":"2011","unstructured":"Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, et al. Emergence of the rtA181T\/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398","journal-title":"BMC Cancer"},{"key":"10223_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1499-3872(16)60064-4","volume":"15","author":"ML Wang","year":"2016","unstructured":"Wang ML, Tang H. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. Hepatobiliary Pancreat Dis Int. 2016;15:579\u2013586","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10223_CR16","doi-asserted-by":"crossref","unstructured":"Lai MW, Liang KH, Yeh CT. Hepatitis B virus preS\/S truncation mutant rtM204I\/sW196* increases carcinogenesis through deregulated HIF1A, MGST2, and TGFbi. Int J Mol Sci. 2020:6366","DOI":"10.3390\/ijms21176366"},{"issue":"Suppl 1","key":"10223_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/liv.13641","volume":"38","author":"M Buti","year":"2018","unstructured":"Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38(Suppl 1):84\u201389","journal-title":"Liver Int"},{"key":"10223_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u2013497","journal-title":"N Engl J Med"},{"key":"10223_CR19","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/hep.24318","volume":"53","author":"C Hongthanakorn","year":"2011","unstructured":"Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854\u20131863","journal-title":"Hepatology"},{"key":"10223_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhep.2010.06.016","volume":"54","author":"W Chotiyaputta","year":"2011","unstructured":"Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2011;54:12\u201318","journal-title":"J Hepatol"},{"key":"10223_CR21","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep4.1247","volume":"2","author":"N Ford","year":"2018","unstructured":"Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2:1160\u20131167","journal-title":"Hepatol Commun"},{"key":"10223_CR22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","volume":"113","author":"JW Shin","year":"2018","unstructured":"Shin JW, Jung SW, Lee SB, Lee BU, Park BR, Park EJ, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir. Am J Gastroenterol. 2018;113:998\u20131008","journal-title":"Am J Gastroenterol"},{"key":"10223_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jvh.13418","volume":"28","author":"J Lee","year":"2021","unstructured":"Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: a nationwide cohort study. J Viral Hepat. 2021;28:353\u2013363","journal-title":"J Viral Hepat"},{"key":"10223_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3851\/IMP3219","volume":"23","author":"S Sheppard-Law","year":"2018","unstructured":"Sheppard-Law S, Zablotska-Manos I, Kermeen M, Holdaway S, Lee A, George J, et al. Factors associated with non-adherence to HBV antiviral therapy. Antivir Ther. 2018;23:425\u2013433","journal-title":"Antivir Ther"},{"key":"10223_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3851\/IMP2482","volume":"18","author":"SG Lim","year":"2013","unstructured":"Lim SG, Aung MO, Chung SW, Soon CS, Mak BH, Lee KH. Patient preferences for hepatitis B therapy. Antivir Ther. 2013;18:663\u2013670","journal-title":"Antivir Ther"},{"key":"10223_CR26","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1111\/liv.14155","volume":"39","author":"P Marcellin","year":"2019","unstructured":"Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39:1868\u20131875","journal-title":"Liver Int"},{"key":"10223_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","volume":"18","author":"JL Hou","year":"2020","unstructured":"Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. Outcomes of long-term treatment of chronic hbv infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18:457-467.e21","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/gut.51.4.597","volume":"51","author":"SG Lim","year":"2002","unstructured":"Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597\u2013599","journal-title":"Gut"},{"key":"10223_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/j.1440-1746.2011.07047.x","volume":"27","author":"KK Lee","year":"2012","unstructured":"Lee KK, Wu DB, Chow PY, Lee VW, Li H. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2012;27:1167\u20131174","journal-title":"J Gastroenterol Hepatol"},{"key":"10223_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/hep.29922","volume":"68","author":"L Xie","year":"2018","unstructured":"Xie L, Yin J, Xia R, Zhuang G. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology. 2018;68:1476\u20131486","journal-title":"Hepatology"},{"key":"10223_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","volume":"51","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403\u2013410","journal-title":"J Hepatol"},{"key":"10223_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167\u2013228","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10223_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","volume":"13","author":"YF Liaw","year":"2019","unstructured":"Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665\u2013673","journal-title":"Hepatol Int"},{"key":"10223_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.29497","volume":"68","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Manolakopoulos S, Su TH, Siakavellas S, Liu CJ, Kourikou A, et al. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. Hepatology. 2018;68:415\u2013424","journal-title":"Hepatology"},{"key":"10223_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63:1481\u20131492","journal-title":"Hepatology"},{"key":"10223_CR36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/apt.13409","volume":"42","author":"YC Chen","year":"2015","unstructured":"Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther. 2015;42:1182\u20131191","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/jvh.12683","volume":"24","author":"CH Hung","year":"2017","unstructured":"Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat. 2017;24:599\u2013607","journal-title":"J Viral Hepat"},{"key":"10223_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/apt.13440","volume":"43","author":"J Ahn","year":"2016","unstructured":"Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, et al. Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US\u2014the ENUMERATE study. Aliment Pharmacol Ther. 2016;43:134\u2013144","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.13272","volume":"42","author":"ML Chang","year":"2015","unstructured":"Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42:243\u2013257","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/00365520903394550","volume":"45","author":"YH Kuo","year":"2010","unstructured":"Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75\u201381","journal-title":"Scand J Gastroenterol"},{"key":"10223_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jir282","volume":"204","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Diss. 2011;204:415\u2013418","journal-title":"J Infect Diss"},{"key":"10223_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","volume":"58","author":"S Chevaliez","year":"2013","unstructured":"Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676\u2013683","journal-title":"J Hepatol"},{"key":"10223_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2013.08.023","volume":"60","author":"G Papatheodoridis","year":"2014","unstructured":"Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol. 2014;60:62\u201368","journal-title":"J Hepatol"},{"key":"10223_CR44","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/jvh.12434","volume":"22","author":"G Papatheodoridis","year":"2015","unstructured":"Papatheodoridis G, Triantos C, Hadziyannis E, Zisimopoulos K, Georgiou A, Voulgaris T, et al. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. J Viral Hepat. 2015;22:1079\u20131087","journal-title":"J Viral Hepat"},{"key":"10223_CR45","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","volume":"60","author":"M Buti","year":"2015","unstructured":"Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457\u20131464","journal-title":"Dig Dis Sci"},{"key":"10223_CR46","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3851\/IMP1921","volume":"16","author":"HL Chan","year":"2011","unstructured":"Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249\u20131257","journal-title":"Antivir Ther"},{"key":"10223_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","volume":"143","author":"SJ Hadziyannis","year":"2012","unstructured":"Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143:629-636.e1","journal-title":"Gastroenterology"},{"key":"10223_CR48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study. J Hepatol. 2017;67:918\u2013924","journal-title":"J Hepatol"},{"key":"10223_CR49","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/S0168-8278(20)30755-8","volume":"73","author":"F van B\u00f6mmel","year":"2020","unstructured":"van B\u00f6mmel F, Stein K, Heyne R, M\u00f6ller H, Petersen J, Buggisch P, et al. Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (LBO06). J Hepatol. 2020;73:S118\u2013S119","journal-title":"J Hepatol"},{"key":"10223_CR50","doi-asserted-by":"crossref","first-page":"19A","DOI":"10.1002\/hep.31008","volume":"72","author":"G Hirode","year":"2020","unstructured":"Hirode G, Choi HSJ, Su T-H, Wong GL-H, Seto W-K, Van Hees S, et al. HBsAg Loss is higher among caucasians compared to asians after stopping nucleos(t)ide analogue therapy: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study) (O023). Hepatology. 2020;72:19A-20A","journal-title":"Hepatology"},{"key":"10223_CR51","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","volume":"14","author":"CH Chen","year":"2020","unstructured":"Chen CH, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, et al. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int. 2020;14:317\u2013325","journal-title":"Hepatol Int"},{"key":"10223_CR52","first-page":"3882","volume":"10","author":"CH Chen","year":"2020","unstructured":"Chen CH, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, et al. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan\u2014a retrospective study. Am J Cancer Res. 2020;10:3882\u20133895","journal-title":"Am J Cancer Res"},{"key":"10223_CR53","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143:963-973.e9","journal-title":"Gastroenterology"},{"key":"10223_CR54","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","volume":"214","author":"C Honer Zu Siederdissen","year":"2016","unstructured":"Honer Zu Siederdissen C, Rinker F, Maasoumy B, Wiegand SB, Filmann N, Falk CS, et al. Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Infect Dis. 2016;214:1492\u20131497","journal-title":"J Infect Dis"},{"key":"10223_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker F, Zimmer CL, Honer Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69:584\u2013593","journal-title":"J Hepatol"},{"issue":"5","key":"10223_CR56","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","volume":"74","author":"M Garcia-Lopez","year":"2021","unstructured":"Garcia-Lopez M, Lens S, Pallett LJ, Testoni B, Rodriguez-Tajes S, Marino Z, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol.\u00a02021;74(5):1064\u20131074","journal-title":"J Hepatol"},{"key":"10223_CR57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1172\/JCI92812","volume":"128","author":"L Rivino","year":"2018","unstructured":"Rivino L, Le Bert N, Gill US, Kunasegaran K, Cheng Y, Tan DZ, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Investig. 2018;128:668\u2013681","journal-title":"J Clin Investig"},{"key":"10223_CR58","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","volume":"217","author":"CL Zimmer","year":"2018","unstructured":"Zimmer CL, Rinker F, H\u00f6ner Zu Siederdissen C, Manns MP, Wedemeyer H, Cornberg M, et al. Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss. J Infect Dis. 2018;217:1656\u20131666","journal-title":"J Infect Dis"},{"issue":"2","key":"10223_CR59","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/hep.31525","volume":"73","author":"YF Liaw","year":"2021","unstructured":"Liaw YF. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: to retreat or not to retreat. Hepatology.\u00a02021;73(2): 843\u2013852","journal-title":"Hepatology"},{"key":"10223_CR60","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57:508\u2013514","journal-title":"J Hepatol"},{"key":"10223_CR61","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00535-018-1502-y","volume":"54","author":"F Suzuki","year":"2019","unstructured":"Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, et al. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol. 2019;54:182\u2013193","journal-title":"J Gastroenterol"},{"key":"10223_CR62","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12072-019-09943-6","volume":"13","author":"X Liang","year":"2019","unstructured":"Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13:260\u2013269","journal-title":"Hepatol Int"},{"key":"10223_CR63","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442\u20132455","journal-title":"N Engl J Med"},{"key":"10223_CR64","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.cgh.2018.10.037","volume":"17","author":"HW Lee","year":"2019","unstructured":"Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, et al. Long-term efficacy of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hbv infection. Clin Gastroenterol Hepatol. 2019;17:1348-1355.e2","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","volume":"71","author":"YS Lim","year":"2019","unstructured":"Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, et al. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trial. J Hepatol. 2019;71:35\u201344","journal-title":"J Hepatol"},{"key":"10223_CR66","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.29187","volume":"66","author":"YS Lim","year":"2017","unstructured":"Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ, Choi J, et al. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology. 2017;66:772\u2013783","journal-title":"Hepatology"},{"issue":"10","key":"10223_CR67","doi-asserted-by":"publisher","first-page":"e01064","DOI":"10.1128\/AAC.01064-18","volume":"62","author":"AL Cathcart","year":"2018","unstructured":"Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection. Antimicrob Agents Chemother. 2018;62(10):e01064\u201318","journal-title":"Antimicrob Agents Chemother"},{"key":"10223_CR68","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886\u2013893","journal-title":"Hepatology"},{"key":"10223_CR69","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468\u2013475","journal-title":"Lancet"},{"key":"10223_CR70","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u20131531","journal-title":"N Engl J Med"},{"key":"10223_CR71","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98\u2013107","journal-title":"Hepatology"},{"key":"10223_CR72","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537\u20131547","journal-title":"Hepatology"},{"key":"10223_CR73","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12072-013-9485-5","volume":"8","author":"J Wang","year":"2014","unstructured":"Wang J, Ma K, Han M, Guo W, Huang J, Yang D, et al. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int. 2014;8:64\u201371","journal-title":"Hepatol Int"},{"key":"10223_CR74","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12072-012-9344-9","volume":"6","author":"K Ma","year":"2012","unstructured":"Ma K, Guo W, Han M, Chen G, Chen T, Wu Z, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. Hepatol Int. 2012;6:735\u2013743","journal-title":"Hepatol Int"},{"issue":"6","key":"10223_CR75","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s12072-019-09992-x","volume":"16","author":"T Chen","year":"2019","unstructured":"Chen T, Yang Z, Choudhury AK, Al Mahtab M, Li J, Chen Y, et al. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. Hepatol Int.\u00a02019;13(6):695\u2013705","journal-title":"Hepatol Int"},{"key":"10223_CR76","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","volume":"66","author":"CL Lai","year":"2017","unstructured":"Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275\u2013281","journal-title":"J Hepatol"},{"key":"10223_CR77","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hep.26376","volume":"58","author":"WK Seto","year":"2013","unstructured":"Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923\u2013931","journal-title":"Hepatology"},{"key":"10223_CR78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","volume":"139","author":"JG Reijnders","year":"2010","unstructured":"Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491\u2013498","journal-title":"Gastroenterology"},{"key":"10223_CR79","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/apt.14560","volume":"47","author":"S Van Hees","year":"2018","unstructured":"Van Hees S, Bourgeois S, Van Vlierberghe H, Serste T, Francque S, Michielsen P, et al. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther. 2018;47:1170\u20131180","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR80","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","volume":"64","author":"WK Seto","year":"2015","unstructured":"Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64:667\u2013672","journal-title":"Gut"},{"key":"10223_CR81","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","volume":"68","author":"KS Liem","year":"2019","unstructured":"Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019;68:2206\u20132213","journal-title":"Gut"},{"key":"10223_CR82","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019;49:218\u2013228","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR83","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/apt.13150","volume":"41","author":"H Chi","year":"2015","unstructured":"Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41:867\u2013876","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR84","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","volume":"14","author":"WJ Jeng","year":"2016","unstructured":"Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, et al. Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients. Clin Gastroenterol Hepatol. 2016;14:1813-1820.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR85","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13:1984-1992.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR86","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.30474","volume":"70","author":"J Liu","year":"2019","unstructured":"Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology. 2019;70:1045\u20131055","journal-title":"Hepatology"},{"key":"10223_CR87","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jvh.13126","volume":"26","author":"Q Ning","year":"2019","unstructured":"Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26:1146\u20131155","journal-title":"J Viral Hepat"},{"key":"10223_CR88","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3851\/IMP2953","volume":"20","author":"W Yan","year":"2015","unstructured":"Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, et al. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Antivir Ther. 2015;20:591\u2013602","journal-title":"Antivir Ther"},{"key":"10223_CR89","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2017.10.003","volume":"147","author":"M Han","year":"2017","unstructured":"Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, et al. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Res. 2017;147:75\u201385","journal-title":"Antiviral Res"},{"key":"10223_CR90","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/jvh.12946","volume":"25","author":"A Shi","year":"2018","unstructured":"Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, et al. CD56(bright) natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a. J Viral Hepat. 2018;25:1352\u20131362","journal-title":"J Viral Hepat"},{"key":"10223_CR91","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61:777\u2013784","journal-title":"J Hepatol"},{"key":"10223_CR92","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3851\/IMP3019","volume":"21","author":"M Han","year":"2016","unstructured":"Han M, Jiang J, Hou J, Tan D, Sun Y, Zhao M, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-alpha2a: 1 year follow-up of the OSST study. Antivir Ther. 2016;21:337\u2013344","journal-title":"Antivir Ther"},{"key":"10223_CR93","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6:25\u201334","journal-title":"J Clin Transl Hepatol"},{"key":"10223_CR94","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","volume":"13","author":"D Wu","year":"2019","unstructured":"Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573\u2013586","journal-title":"Hepatol Int"},{"key":"10223_CR95","unstructured":"Meifang Han DW, Deming Tan, Yongping Chen, Xinyue Chen, Xiaoguang Dou, Ke Ma, Li Sun, Qin Ning. Combination\/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study): an interim analysis. Hepatology. 2017;66, S1, 13A"},{"key":"10223_CR96","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.12999","volume":"26","author":"P Lampertico","year":"2019","unstructured":"Lampertico P, Brunetto MR, Craxi A, Gaeta GB, Rizzetto M, Rozzi A, et al. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B \u201ce\u201d antigen-negative chronic hepatitis B genotype D. J Viral Hepat. 2019;26:118\u2013125","journal-title":"J Viral Hepat"},{"key":"10223_CR97","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2:177\u2013188","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10223_CR98","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1093\/infdis\/jix382","volume":"216","author":"TH Su","year":"2017","unstructured":"Su TH, Kao JH. Unmet needs in clinical and basic hepatitis B virus research. J Infect Dis. 2017;216:S750\u2013S756","journal-title":"J Infect Dis"},{"issue":"2","key":"10223_CR99","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/cells9020493","volume":"9","author":"M Papatheodoridi","year":"2020","unstructured":"Papatheodoridi M, Papatheodoridis G. Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B. Cells. 2020;9(2):493","journal-title":"Cells"},{"key":"10223_CR100","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1136\/gutjnl-2019-319648","volume":"68","author":"JH Kao","year":"2019","unstructured":"Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut. 2019;68:2105\u20132106","journal-title":"Gut"},{"key":"10223_CR101","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.26549","volume":"58","author":"WJ Jeng","year":"2013","unstructured":"Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888\u20131896","journal-title":"Hepatology"},{"key":"10223_CR102","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","volume":"18","author":"TN Tseng","year":"2020","unstructured":"Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, et al. Incidence and Factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL. Clin Gastroenterol Hepatol. 2020;18:2803-2812.e2802","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR103","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/infdis\/jix690","volume":"217","author":"TH Su","year":"2018","unstructured":"Su TH, Yang HC, Tseng TC, Liou JM, Liu CH, Chen CL, et al. Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy. J Infect Dis. 2018;217:1193\u20131201","journal-title":"J Infect Dis"},{"key":"10223_CR104","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018;24:997\u20131003","journal-title":"Clin Microbiol Infect"},{"key":"10223_CR105","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","volume":"18","author":"SM Chiu","year":"2020","unstructured":"Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, et al. Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy. Clin Gastroenterol Hepatol. 2020;18:2989-2997.e2983","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR106","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.cgh.2016.03.024","volume":"14","author":"YC Hsu","year":"2016","unstructured":"Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, et al. Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in E antigen-negative patients. Clin Gastroenterol Hepatol. 2016;14:1490-1498.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR107","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/ajg.2016.109","volume":"111","author":"CC Wang","year":"2016","unstructured":"Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg. Am J Gastroenterol. 2016;111:1286\u20131294","journal-title":"Am J Gastroenterol"},{"key":"10223_CR108","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/jvh.13211","volume":"27","author":"M Papatheodoridi","year":"2020","unstructured":"Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, et al. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat. 2020;27:118\u2013126","journal-title":"J Viral Hepat"},{"key":"10223_CR109","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1053\/j.gastro.2018.03.066","volume":"154","author":"YF Liaw","year":"2018","unstructured":"Liaw YF, Jeng WJ, Chang ML. HBsAg kinetics in retreatment decision for off-therapy hepatitis B flare in HBeAg-negative patients. Gastroenterology. 2018;154:2280\u20132281","journal-title":"Gastroenterology"},{"key":"10223_CR110","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/apt.15058","volume":"49","author":"YC Hsu","year":"2019","unstructured":"Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107\u2013115","journal-title":"Aliment Pharmacol Ther"},{"key":"10223_CR111","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","volume":"70","author":"WK Seto","year":"2021","unstructured":"Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut.\u00a02021;70:775\u2013783","journal-title":"Gut"},{"key":"10223_CR112","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jfma.2017.11.012","volume":"117","author":"CH Tseng","year":"2018","unstructured":"Tseng CH, Hsu YC, Chang CY, Tseng TC, Wu MS, Lin JT, et al. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. J Formos Med Assoc. 2018;117:915\u2013921","journal-title":"J Formos Med Assoc"},{"key":"10223_CR113","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","volume":"17","author":"H Chi","year":"2019","unstructured":"Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol. 2019;17:182\u2013191","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR114","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 2016;65:700\u2013710","journal-title":"J Hepatol"},{"issue":"1","key":"10223_CR115","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.31026","volume":"72","author":"I Carey","year":"2016","unstructured":"Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, et al. Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology\u00a02020;72(1):42\u201357","journal-title":"Hepatology"},{"key":"10223_CR116","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/jvh.13068","volume":"26","author":"H Kranidioti","year":"2019","unstructured":"Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, et al. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2019;26:697\u2013709","journal-title":"J Viral Hepat"},{"key":"10223_CR117","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","volume":"218","author":"C Honer Zu Siederdissen","year":"2018","unstructured":"Honer Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients. J Infect Dis. 2018;218:1480\u20131484","journal-title":"J Infect Dis"},{"key":"10223_CR118","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jvh.13091","volume":"26","author":"M Papatheodoridi","year":"2019","unstructured":"Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26:936\u2013941","journal-title":"J Viral Hepat"},{"key":"10223_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.005","author":"MJ Sonneveld","year":"2020","unstructured":"Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, et al. Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg Levels\u2014A Multicenter Study (CREATE). Clin Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR120","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","volume":"222","author":"R Fan","year":"2020","unstructured":"Fan R, Peng J, Xie Q, Tan D, Xu M, Niu J, et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B. J Infect Dis. 2020;222:611\u2013618","journal-title":"J Infect Dis"},{"key":"10223_CR121","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","volume":"18","author":"R Fan","year":"2020","unstructured":"Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, et al. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol. 2020;18:719-727.e7","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10223_CR122","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0168-8278(03)00394-5","volume":"39","author":"SH Ryu","year":"2003","unstructured":"Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003;39:614\u2013619","journal-title":"J Hepatol"},{"key":"10223_CR123","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2893.2009.01178.x","volume":"17","author":"L Wang","year":"2010","unstructured":"Wang L, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298\u2013304","journal-title":"J Viral Hepat"},{"key":"10223_CR124","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/infdis\/jix025","volume":"215","author":"J Cao","year":"2017","unstructured":"Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, et al. Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study. J Infect Dis. 2017;215:581\u2013589","journal-title":"J Infect Dis"},{"key":"10223_CR125","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/1751-2980.12654","volume":"19","author":"F Liu","year":"2018","unstructured":"Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, et al. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis. 2018;19:561\u2013571","journal-title":"J Dig Dis"},{"key":"10223_CR126","doi-asserted-by":"publisher","first-page":"O687","DOI":"10.1111\/1469-0691.12605","volume":"20","author":"D He","year":"2014","unstructured":"He D, Guo S, Zhu P, Tao S, Li M, Huang H, et al. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect. 2014;20:O687-O693","journal-title":"Clin Microbiol Infect"},{"key":"10223_CR127","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijid.2015.10.019","volume":"43","author":"YW Qiu","year":"2016","unstructured":"Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, et al. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis. 2016;43:43\u201348","journal-title":"Int J Infect Dis"},{"key":"10223_CR128","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab007","author":"DS Song","year":"2021","unstructured":"Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, et al. Improving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B. Clin Infect Dis. 2021. https:\/\/doi.org\/10.1093\/cid\/ciab007","journal-title":"Int J Infect Dis"},{"key":"10223_CR129","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3851\/IMP3256","volume":"23","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, et al. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23:677\u2013685","journal-title":"Antivir Ther"},{"key":"10223_CR130","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1038\/ctg.2017.51","volume":"8","author":"YF Lam","year":"2017","unstructured":"Lam YF, Seto WK, Wong D, Cheung KS, Fung J, Mak LY, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;8:e125","journal-title":"Clin Transl Gastroenterol"},{"issue":"Suppl 1","key":"10223_CR131","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.13654","volume":"38","author":"F van Bommel","year":"2018","unstructured":"van Bommel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int. 2018;38(Suppl 1):90\u201396","journal-title":"Liver Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10223-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10223-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T11:19:27Z","timestamp":1699269567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10223-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10223"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10223-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"31 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JHK: serves as advisor\/consultant for AbbVie, Fujirebio Incorporation, Gilead Sciences, GlaxoSmithKline, Janssen, and Sysmex. MFY: serves as advisor\/consultant for AbbVie, Aligos therapeutics, Arbutus Biopharma, Bristol Myer Squibb, Dicerna Pharmaceuticals, Finch Therapeutics, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals, Roche and receives grant\/ research supports from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Springbank Pharmaceuticals, Sysmex Corporation, Roche. Others: Nothing to disclose regarding this submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}